BLTE | tickerfilter.com

Fundamental analysis

Profitability 0%

Dept financing 0%

Liquidity 0%

Performance 0%

Performance

5 Days

-2.41%

1 Month

-5.31%

3 Months

15.60%

6 Months

156.70%

1 Year

174.25%

2 Year

272.05%

Key data

Stock price

$173.30

P/E Ratio

0.00

DAY RANGE

$168.21 - $177.92

EPS

N/A

52 WEEK RANGE

$49.00 - $200.00

52 WEEK CHANGE

$158.85

MARKET CAP

1.139 B

YIELD

N/A

SHARES OUTSTANDING

30.612 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

08-08-2025

BETA

1.35

PUBLIC FLOAT

AVERAGE 10 VOLUME

$254,200

AVERAGE 30 VOLUME

$197,278

Company detail

CEO: Yue H. Lin
Region: US
Website: belitebio.com
Employees: 10
IPO year: 2022

Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Belite Bio, Inc engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue.

BLTE - BELITE BIO, INC